Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Endocrine adverse effects of omeprazole.

Literature DB >> 1392958

Endocrine adverse effects of omeprazole.

M Lindquist¹, I R Edwards.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Omeprazole

Year: 1992 PMID： 1392958 PMCID： PMC1882563 DOI： 10.1136/bmj.305.6851.451

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

4 in total

1. Painful gynaecomastia during omeprazole therapy.

Authors: C Convens; J Verhelst; C Mahler
Journal: Lancet Date: 1991-11-02 Impact factor: 79.321

2. Gynecomastia during omeprazole therapy.

Authors: L Santucci; F Farroni; S Fiorucci; A Morelli
Journal: N Engl J Med Date: 1991-02-28 Impact factor: 91.245

3. Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis?

Authors: P April; M Abeles; H Baraf; S Cohen; N Curran; M Doucette; B Ekholm; B Goldlust; C M Knee; E Lee
Journal: Semin Arthritis Rheum Date: 1990-02 Impact factor: 5.532

4. Inhibition of human liver cytochrome P-450 by omeprazole.

Authors: J C Jensen; R Gugler
Journal: Br J Clin Pharmacol Date: 1986-03 Impact factor: 4.335

4 in total

11 in total

1. Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System.

Authors: Alfonso Carvajal; Diego Macias; Angélica Gutiérrez; Sara Ortega; María Sáinz; Luis H Martín Arias; Alfonso Velasco
Journal: Drug Saf Date: 2007 Impact factor: 5.606

2. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts.

Authors: S Olsson
Journal: Drug Saf Date: 1998-07 Impact factor: 5.606

3. Treatment of refractory ulcerative oesophagitis with omeprazole.

Authors: P Alliët; M Raes; P Gillis; M Callewaert; A Zimmermann
Journal: Arch Dis Child Date: 1993-04 Impact factor: 3.791

Review 4. Safety of acid-suppressing drugs.

Authors: R A Smallwood; R G Berlin; N Castagnoli; H P Festen; C J Hawkey; S K Lam; M J Langman; P Lundborg; A Parkinson
Journal: Dig Dis Sci Date: 1995-02 Impact factor: 3.199

Endocrine adverse effects of omeprazole.

1. Painful gynaecomastia during omeprazole therapy.

2. Gynecomastia during omeprazole therapy.

3. Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis?

4. Inhibition of human liver cytochrome P-450 by omeprazole.

1. Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System.

2. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts.

3. Treatment of refractory ulcerative oesophagitis with omeprazole.

Review 4. Safety of acid-suppressing drugs.

5. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs.

6. Local protective effects of oral 45S5 bioactive glass on gastric ulcers in experimental animals.

Review 7. A comparative overview of the adverse effects of antiulcer drugs.

8. Transmucosal gastric leak induced by proton pump inhibitors.

Review 9. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

10. Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review.